Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...

A research team affiliated with UNIST has unveiled a novel AI system capable of grading and providing detailed feedback on ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In 2015, AI in drug discovery was still a theoretical pursuit – exciting, but unproven. A few early start-ups were applying deep learning to virtual screening and molecular modelling, but the industry ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Andriy Blokhin has 5+ years of professional experience in public accounting, personal investing, and as a senior auditor with Ernst & Young. Thomas J. Brock is a CFA and CPA with more than 20 years of ...

Several measurement techniques used in the life sciences gather data for many more variables per sample than the typical number of samples assayed. For instance, DNA microarrays and mass spectrometers ...

Decision-making inherently involves cause–effect relationships that introduce causal challenges. We argue that reliable algorithms for decision-making need to build upon causal reasoning. Addressing ...